1文献来源Zhang YX,Sheng J,Kang SY,et al.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell...1文献来源Zhang YX,Sheng J,Kang SY,et al.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer：A meta-analysis[J].PLo S One,2014,9（9）：e107161.2证据水平1a。展开更多
1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Cli...1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。展开更多
1文献来源
Wu YL, Intercalated Lee JS, Thongprasert S, combination of chemotherapy et al. andErlotinib for patients with advanced stage non-smallcell lung cancer （FASTACT-2）： A randomised, double-blind trial[J]. ...1文献来源
Wu YL, Intercalated Lee JS, Thongprasert S, combination of chemotherapy et al. andErlotinib for patients with advanced stage non-smallcell lung cancer （FASTACT-2）： A randomised, double-blind trial[J]. Lancet Oncol, 2013,14（8）： 777-786.展开更多
文摘1文献来源Zhang YX,Sheng J,Kang SY,et al.Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer：A meta-analysis[J].PLo S One,2014,9（9）：e107161.2证据水平1a。
文摘1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phaseⅢKEYNOTE-604 study[J].J Clin Oncol,2020,38(21):2369-2379.2证据水平1b。3背景依托泊苷联合铂类是广泛期小细胞肺癌(extensive-stage small-cell lung cancer,ES-SCLC)一线标准治疗方案之一。帕博丽珠单抗单药在小细胞肺癌中显示出抗肿瘤活性。
文摘1文献来源
Wu YL, Intercalated Lee JS, Thongprasert S, combination of chemotherapy et al. andErlotinib for patients with advanced stage non-smallcell lung cancer （FASTACT-2）： A randomised, double-blind trial[J]. Lancet Oncol, 2013,14（8）： 777-786.
